IGF-1 LR3 — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 6 sources[1,2,3,4,5,6].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products | ICH Harmonised Tripartite Guideline | 1999 |
| 2 | General Chapter ⟨85⟩ Bacterial Endotoxins Test | United States Pharmacopeia — National Formulary (USP–NF) | 2024 |
| 3 | ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories | ISO/IEC Standard | 2017 |
| 4 | Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions | Expert Review of Proteomics | 2019 |
| 5 | Quality of peptide products obtained from unregulated online suppliers: an analytical survey | Journal of Pharmaceutical Sciences | 2024 |
| 6 | Protein aggregation — pathways and influencing factors | International Journal of Pharmaceutics | 2010 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 0 | — |
| Evidence syntheses | 0 | none |
| Comment periods | 1 | Draft monograph: IGF-1 LR3 |
| Indication assessments | 2 | Lean-mass preservation · GH axis |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
- United States Pharmacopeial Convention. General Chapter ⟨85⟩ Bacterial Endotoxins Test. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
- Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.
- Wang W, Nema S, Teagarden D. Protein aggregation — pathways and influencing factors. International Journal of Pharmaceutics 2010;390(2):89–99. doi:10.1016/j.ijpharm.2010.02.025 · PMID 20188795
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.